HighTide Therapeutics, Inc.

SEHK:2511 Stock Report

Market Cap: HK$540.5m

HighTide Therapeutics Management

Management criteria checks 1/4

HighTide Therapeutics' CEO is Liping Liu, appointed in Feb 2018, has a tenure of 6.75 years. total yearly compensation is CN¥14.66M, comprised of 24.1% salary and 75.9% bonuses, including company stock and options. directly owns 0.96% of the company’s shares, worth HK$5.20M. The average tenure of the management team and the board of directors is 2.8 years and 1.8 years respectively.

Key information

Liping Liu

Chief executive officer

CN¥14.7m

Total compensation

CEO salary percentage24.1%
CEO tenure6.8yrs
CEO ownership1.0%
Management average tenure2.8yrs
Board average tenure1.8yrs

Recent management updates

Recent updates

We're A Little Worried About HighTide Therapeutics' (HKG:2511) Cash Burn Rate

Oct 05
We're A Little Worried About HighTide Therapeutics' (HKG:2511) Cash Burn Rate

Is HighTide Therapeutics (HKG:2511) In A Good Position To Invest In Growth?

Jun 21
Is HighTide Therapeutics (HKG:2511) In A Good Position To Invest In Growth?

CEO Compensation Analysis

How has Liping Liu's remuneration changed compared to HighTide Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥601m

Mar 31 2024n/an/a

-CN¥770m

Dec 31 2023CN¥15mCN¥4m

-CN¥939m

Sep 30 2023n/an/a

-CN¥803m

Jun 30 2023n/an/a

-CN¥666m

Mar 31 2023n/an/a

-CN¥428m

Dec 31 2022CN¥7mCN¥4m

-CN¥190m

Dec 31 2021CN¥7mCN¥3m

-CN¥221m

Compensation vs Market: Liping's total compensation ($USD2.02M) is above average for companies of similar size in the Hong Kong market ($USD232.96K).

Compensation vs Earnings: Liping's compensation has increased whilst the company is unprofitable.


CEO

Liping Liu (54 yo)

6.8yrs

Tenure

CN¥14,663,000

Compensation

Dr. Liping Liu has been the Chief Executive Officer and Executive Director of HighTide Therapeutics, Inc. since February 28, 2018 and its chairwoman since December 22, 2023 She has been the Chief Executive...


Leadership Team

NamePositionTenureCompensationOwnership
Liping Liu
CEO & Chairwoman6.8yrsCN¥14.66m0.96%
HK$ 5.2m
Meng Yu
Deputy GM & Executive Director7.4yrsCN¥10.83m0.34%
HK$ 1.8m
Koon Yin Sim
Chief Financial Officer1.9yrsno datano data
Leigh Anne MacConell
Chief Development Officer3.8yrsno datano data
Yu Li
VP & Joint Company Secretary1.5yrsno datano data
Pik Man Chu
Joint Company Secretaryless than a yearno datano data

2.8yrs

Average Tenure

50.5yo

Average Age

Experienced Management: 2511's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Liping Liu
CEO & Chairwoman6.8yrsCN¥14.66m0.96%
HK$ 5.2m
Meng Yu
Deputy GM & Executive Director1.5yrsCN¥10.83m0.34%
HK$ 1.8m
Gwen A. Melincoff
Member of the Scientific Advisory Boardno datano datano data
Bo Tan
Independent Non-Executive Directorless than a yearCN¥4.00kno data
Lawrence Goldkind
Member of Scientific Advisory Boardno datano datano data
Xun Zhu
Non-Executive Director4yrsCN¥1.84m0.17%
HK$ 899.5k
Li Jin
Independent Non-Executive Directorless than a yearCN¥4.00kno data
Kris Kowdley
Member of Scientific Advisory Boardno datano datano data
Feng Jiang
Non-Executive Director2yrsno datano data
Lixiong Ma
Non-Executive Director3yrsCN¥8.90m0.19%
HK$ 1.0m
Tak Wai Hung
Independent Non-Executive Directorless than a yearCN¥4.00kno data
Adrian M. Di Bisceglie
Member of Scientific Advisory Boardno datano datano data

1.8yrs

Average Tenure

54yo

Average Age

Experienced Board: 2511's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.